江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露通过药品GMP符合性检查的公告

Group 1 - The company’s subsidiary, Hangzhou Ausino Biotechnology Co., Ltd., has received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, confirming that the active pharmaceutical ingredient (API) of Ograpivir Sodium has passed the GMP compliance check [1] - The inspection took place from January 14 to January 16, 2026, covering specific production lines and workshops related to the API [1] - The successful GMP compliance check reinforces the company's commitment to leading production and quality management systems, marking a milestone for the CDMO business in extending from advanced intermediates to APIs [1]